Glen Eagle Advisors’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-33
Closed -$4.99K 1190
2022
Q3
$4.99K Buy
+33
New +$4.89K ﹤0.01% 707

Other funds holding BHVN

Glen Eagle Advisors's BHVN Position: Q4 2022 in Review

Glen Eagle Advisors sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 33 shares — an estimated $4.99K sold.

Glen Eagle Advisors first reported a position in BHVN in Q3 2022 and held it in 1 quarter. The position peaked at $4.99K in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Glen Eagle Advisors reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Glen Eagle Advisors sold 33 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $4.99K.
  • Glen Eagle Advisors first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2022 and held it in 1 quarter.
  • Glen Eagle Advisors's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $4.99K in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Glen Eagle Advisors's 13F filing for Q4 2022, filed 13 Aug 2024.